Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
about
Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?Understanding cachexia as a cancer metabolism syndromeDistinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3Protein calorie malnutrition, nutritional intervention and personalized cancer care.Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition.The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse.MST1, a key player, in enhancing fast skeletal muscle atrophy.IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia.Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exerciseC/EBPβ mediates tumour-induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wastingJAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.Molecular and cellular mechanisms of skeletal muscle atrophy: an update.p38β MAPK upregulates atrogin1/MAFbx by specific phosphorylation of C/EBPβ.Combination of exercise training and erythropoietin prevents cancer-induced muscle alterationsSignaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2.The therapeutic potential of IGF-I in skeletal muscle repair.Motor protein function in skeletal abdominal muscle of cachectic cancer patients.Cachexia and sarcopenia: emerging syndromes of importance in dogs and cats.Muscle atrophy in aging and chronic diseases: is it sarcopenia or cachexia?Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches.Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice.Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90.Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course of Muscle Wasting in Experimental Cancer Cachexia.Are there any benefits of exercise training in cancer cachexia?Improvement of skeletal muscle performance in ageing by the metabolic modulator TrimetazidineS100B protein in skeletal muscle regeneration: regulation of myoblast and macrophage functions.MuRF-1 and p-GSK3β expression in muscle atrophy of cirrhosis.Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival.The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice.Serum leptin is not correlated with body fat in severe food restriction.In vivo measurement of hindlimb neuromuscular function in mice.Role of cyclic AMP sensor Epac1 in masseter muscle hypertrophy and myosin heavy chain transition induced by β2-adrenoceptor stimulation.Modulating Metabolism to Improve Cancer-Induced Muscle Wasting.The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting.Lung Cancer Cachexia: Can Molecular Understanding Guide Clinical Management?
P2860
Q28068034-3C7E32B4-DA0E-48BB-B704-5D424FFA7662Q28069390-88BA974D-E925-449F-BD19-96449EA410CDQ28542391-6E0E69D3-FCC0-49FE-8940-12D79F665A87Q33618955-2BFE7A8A-A972-4589-A44C-7C5070F25B92Q33737527-1E8BC888-BE76-4A10-8FA0-C04E46FC3E40Q34031423-A4D37B85-9CF7-47D4-9A55-3E4E868AA158Q34572209-E0DCDB2E-6EDC-40B8-A0C4-AD279B6A914EQ35053581-0E57FADB-FF36-4352-80ED-6936277A8633Q35053606-DCE214F0-0DA9-4ECC-BFBD-74BCBE6327F7Q35422257-13BE6462-7B77-4EBB-933F-E27E5EC25C06Q36176015-8D2BD2A2-6F8D-4D1C-B060-55888A4DEB6CQ36179105-5423ABD5-6F8A-4BBD-ACD3-EC2A627411E1Q36500673-3318E5E9-CD88-4669-811D-85BB26BEBAF2Q36685366-1004AD0E-9BA6-4D16-A36A-DF1CAC622580Q36945094-C117A311-DAF7-4206-9559-874447D07674Q37068201-F0C7157F-838C-4AC5-991E-7D7893D311F9Q37562334-95C226BB-5073-412F-B2F0-95993323C822Q37960096-90835BEC-7436-482A-ACD4-DDAE0A66ECB7Q38024726-78C42C21-46CD-4DE1-80DE-A1FDFA875CFEQ38587970-C5AB58CA-8AA6-43C8-A04B-C039B0A8D3BFQ39093151-4B8B3046-305D-46F0-ABB4-9583E996ABC5Q41701219-50090721-43D8-4589-AF2D-D8DF3C8A206BQ42155053-6B86A3D9-6BBE-4675-B606-9C1E4A1505FEQ42199742-AEC03C67-4457-4716-ADBB-25C61F5D1B21Q42793119-C63DF3B8-87AA-47F8-BC18-B9495CBA68B5Q42917237-1215B712-1C4F-498A-AA32-5C340AAE0F6BQ44315702-3913077D-07EC-471D-A5D6-A57FB0BF332EQ47095769-9F687687-1A93-40E4-813E-A102C19FBA12Q47117911-F4C23F41-A6CB-4AD3-8222-53451D00B685Q47966942-2488F4C4-0B1B-4085-85F9-7CAA9BBBB7DFQ51398850-90DBFAC5-07D9-4060-A1D3-825832BF1DDCQ52654611-8C62AA9F-F4EE-43F7-949A-8470CBD64216Q55301138-5EB3237B-6972-4C9E-97ED-9A5DD6FF5716Q55653938-A9C205C7-D703-411B-8571-043E9173F1E0Q57164295-D5CEB19F-194D-4883-9021-4C008A9950C8
P2860
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
@en
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
@nl
type
label
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
@en
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
@nl
prefLabel
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
@en
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
@nl
P2093
P2860
P50
P356
P1476
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
@en
P2093
Domiziana Costamagna
Francesco Maria Baccino
Maurizio Muscaritoli
Paola Costelli
Valerio Giacomo Minero
P2860
P304
P356
10.1002/IJC.25146
P577
2010-10-01T00:00:00Z